Nerve growth factor (NGF) has important functions during embryonic development and on various tissues and organs under normal and pathological conditions during the extrauterine life. RT-PCR analysis and immunological methods demonstrate that human umbilical vein endothelial cells (HUVECs) express the NGF receptors trkA NGFR and p75 NTR . NGF treatment caused a rapid phosphorylation of trkA NGFR in HUVECs, determining a parallel increase of phosphorylated ERK 1/2 . Accordingly, NGF induced a significant increase in HUVEC proliferation that was abolished by the trkA NGFR inhibitor K252a. Also, HUVECs express significant levels of NGF under standard culture conditions that were up-regulated during serum starvation. Endogenous NGF was responsible for the basal levels of trkA NGFR and ERK 1/2 phosphorylation observed in untreated HUVEC cultures. Finally, NGF exerted a potent, direct, angiogenic activity in vivo when delivered onto the chorioallantoic membrane of the chicken embryo. The data indicate that NGF may play an important role in blood vessel formation in the nervous system and in several pathological processes, including tumors and inflammatory diseases. Unraveling mechanisms of NGF-dependent angiogenesis could provide valuable tools for novel therapeutic approaches in antiangiogenic therapy.
It has been recently reported that NGF exerts indirect proangiogenic effects mediated by specific angiogenic factors in the developing CNS (14) and that it induces increased expression of inflammatory markers in skin vessels (15) . An elevated grade of vascularization is a common feature of many malignancies of the CNS, for example gliomas (16) .
In the present work, we addressed the possibility that NGF may exert a direct mitogenic effect on endothelial cells in vitro and in vivo. To this purpose, we investigated the presence of NGF receptors in human umbilical vein endothelial cells (HUVECs) and the ability of the growth factor to induce a mitogenic response in these cells.
Also, we investigated the capability of NGF to induce neovascularization in the chick embryo chorioallantoic membrane (CAM), a consolidated assay to assess the angiogenic potential of EGF (17) .
MATERIALS AND METHODS

Cell cultures and reagents
All materials and media were from Invitrogen Srl (San Giuliano Milanese, Italy), unless otherwise specified. Antibodies were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA), unless otherwise specified. HUVECs were obtained from human umbilical cords from healthy women who underwent uncomplicated term pregnancies, as described elsewhere (18) .
Cells were grown in gelatin-coated plastic in medium M199 supplemented with endothelial cell growth supplement (ECGS; 20 µg/ml), heparin (1625 I.U./ml; Sigma-Aldrich, Milan, Italy), and 20 % fetal calf serum (FCS).
PC12 cells, originally from the National Institutes of Health (Bethesda, MD), were cultured in Dulbecco's modified Eagle's medium (DMEM) with 7.5 % horse serum and 7.5% FCS, penicillin (100 U/ml), and streptomycin (100 µg/ml).
The human glioblastoma cell line U373 MG (from American Type Culture Collection, ATCC, Manassas, VA) was cultured in DMEM with 10% FCS, penicillin (100 U/ml), and streptomycin (100 µg/ml).
Reverse transcriptase-polymerase chain reaction (RT-PCR)
Total RNA from cells grown to 80% confluence was isolated after solubilization in guanidinium thiocyanate by phenol-chloroform extraction and precipitation (19) . For first-strand cDNA synthesis, we reverse-transcribed 5 µg of total RNA by using 25 µg/ml oligo (dT) [12] [13] [14] [15] [16] [17] [18] primer in a final volume of 20 µl, in the presence or absence of 200 units of M-MLV reverse transcriptase. After first RNA denaturation at 70ûC for 15 min, enzyme was added and the reaction mixture was incubated at 42ûC for 1 h and subsequently heated for additional 5 min at 95ûC. We performed PCR in a total volume of 25 µl containing 1 µl of the cDNA reaction mixture, 5 pmol of each upstream and downstream primer, and 1.2 units of Taq polymerase. The amplification program for p75 NTR and TrkA NGFR consisted in 40 cycles of denaturation at 95ûC for 45 seconds, annealing at 62ûC for 1 min, and elongation at 72ûC for 1 min. The amplification program for NGF consisted in 35 cycles of denaturation at 95ûC for 45 seconds, annealing at 58ûC for 1 min, and elongation at 72ûC for 1 min. The cycle programs were preceded by a denaturation step at 94ûC for 3 min and followed by an additional at 72ûC for 10 min. PCR products were analyzed by electrophoresis on 1.5% agarose gel and were visualized with ethidium bromide. The following RNA transcripts were detected via amplification of the corresponding cDNAs: a) p75
NTR with a primer pair already described (20) , yielding a 663 base-pair PCR product; b) trkA NGFR with a primer pair previously described (21) , with an amplicon length of 476 base pairs; and c) human NGF with a primer pair composed of the sense 5'-GCGGCGACTCCGTTCACCCCG and the antisense primer 5'-GCTTGCCATCCATGGTCAGCGCC, with an amplicon of 412 base pair.
Immunoprecipitation and immunoblot analysis
We used untreated HUVEC (2×10 7 cells) for trkA NGFR and p75 NTR immunoprecipitation experiments. PC12 cells (1×10 6 ) were used as positive control. For signal transduction experiments, after a 24-h starvation, HUVECs were rinsed with warm PBS and were incubated for 15 min in the presence or the absence of NGF (50 ng/ml), and with K252a (200 nM) (Fermentek Biotechnology, Jerusalem, Israel) added 5 min before NGF. Cells were lysed in lysis buffer [150 mM NaCl; 50 mM Tris-HCl, pH 7.5; 5 mM ethylene diamine tetraacetate (EDTA), 1 mM Na 3 VO 4 , 30 mM Na pyrophosphate, 50 mM NaF, 1 mM phenylmethylsulfonyl fluoride (PMSF), 5 µg/ml aprotinin, 2 µg/ml leupeptin, 1 µg/ml pepstatin, 10% glycerol, and 0.2% Triton x-100]. The supernatants were incubated overnight at 4ûC with either 203 rabbit polyclonal antitrkA NGFR (22) or rabbit polyclonal anti-p75 NTR . Complexes were precipitated with protein ASepharose (Sigma-Aldrich) for 2 h at 4ûC. After three washes with lysis buffer, the conjugated material was eluted from the beads by boiling in sodium dodecyl sulfate (SDS) loading buffer (20% glycerol; 10% 2-mercaptoethanol; 4% SDS; 100 mM Tris-HCl, pH 6.8; 0.2% bromophenol blue), subjected to electrophoresis on 10% SDS-polyacrylamide gel electrophoreses (PAGE) gel, and then transferred onto Hybond ECL nitrocellulose membrane (Amersham Life Science, Buckinghamshire, UK) for 1 h and analyzed by immunoblotting with a primary specific antibody (1:1000) and with the secondary peroxidase-conjugated anti-rabbit. For trkA NGFR phosphorylation the membrane was incubated with a monoclonal anti-phosphotyrosine (PY) antibody diluted 1:1000. Staining was performed by a chemoluminescence assay (ECL; Amersham Italia S.r.l., Milan, Italy).
Western blot analysis
Subconfluent HUVEC grown in 60 mm plastic Petri dishes were starved for 24 h and then incubated in the presence of NGF (50 ng/ml) for 15 min, either alone, with K252a (200 nM), or with PD98059 (50 µM) (Sigma-Aldrich) and added 5 min and 1 h, respectively, before NGF. Inhibitors were used alone in control experiments. Cells were then lysed in NP-40 lysis buffer (50 mM HEPES, pH 7.6; 150 mM NaCl; 50 µM NaF; 2 mM EDTA; 1 mM Na 3 VO 4 ; 1% NP-40; 2 mM PMSF). Cellular extracts (50 µg) were boiled for 10 min in SDS loading buffer, separated by SDS-PAGE (12%) electrophoresis, transferred to a nitrocellulose membrane, and probed with specific rabbit polyclonal anti-pMAPK (New England BioLabs, Inc. Beverly, MA) (1:1000) and with the secondary peroxidase-conjugated anti-rabbit Ab (1:10000), which was finally detected by enhanced chemiluminescence (ECL; Amersham Italia S.r.l., Milan, Italy).
HUVEC proliferation and viability assay
HUVEC were seeded at 1 × 10 3 cells/well into 96-multiwell plates in M199 with ECGS, 20% FCS, and heparin. After 24 h, medium was replaced with fresh complete medium containing graded concentrations of NGF (10, 20, 30, 40 , and 50 ng/ml; Alomone Labs, Jerusalem, Israel) and incubated for 96 h. NGF or VEGF neutralizing antibodies (1 µg/ml) were added together with NGF to HUVECs and incubated along the entire experiment. The MAPK inhibitor PD98059 (50 µM) was added 1 h before incubation of HUVEC with NGF.
At the end of experiments, cells were stained with 0.5% crystal violet solution for 30 min, washed with bidistilled water, and lysed in 10% acetic acid for 15 min. Optical density was read at 570 nm.
Immunocytochemistry
Immunocytochemical analysis was performed to detect basal trkA NGFR , p75 NTR , and NGF expression in untreated, subconfluent HUVEC cultured in 35 mm Petri dishes. In addition, NGF levels were examined in HUVEC cultures after 24 and 48 h of starvation. Cells were fixed 5 min in 2% glutaraldehyde in Hank's balanced salt solution (pH 7.3), diluted 1:1 with culture medium; then 10 min in 2% glutaraldehyde. Cells were washed 30 min with PBS, blocking buffer [PBS, 1% bovine serum albumin (BSA)] was then added to the dishes and gently shaken for 15 min at room temperature. Fixed cells were incubated with either a rabbit polyclonal anti-trkA NGFR , an anti-p75 NTR , or an anti-NGF antibody, diluted 1:100 (anti-trkA NGFR ) or 1:50 (anti-NGF p75 and anti-NGF) in blocking buffer and kept to shake gently overnight at 4ûC. In control experiments, primary antiserum was replaced by normal rabbit serum. Dishes were then washed twice with PBS and incubated for 20 min with a biotinylated goat anti-rabbit IgG, according to the manufacturer instructions (Dako LSAB2 System, Peroxidase. Dako Corporation, Carpinteria, CA). After two rinses with PBS, fresh streptavidin-horse radish peroxidase solution was added for 20 min. Dishes were then washed in PBS, and immunoreactivity was visualized by means of the diaminobenzidine method.
Chick embryo chorioallantoic membrane assay
Fertilized White Leghorn chicken eggs (30/group) were incubated under constant humidity at 37ûC. On the third day of incubation, a square window was opened in the shell after removal of 2-3 ml of albumin to detach the developing CAM from the shell. The window was sealed with a glass of the same dimension, and the eggs were returned to the incubator.
CAMs were treated at day 8 with 400 ng/embryo of mouse NGF 2.5S (Alomone Labs, Jerusalem, Israel) dissolved in 2 µl PBS and adsorbed on 1 mm 3 sterilized gelatin sponges (Gelfoam, Upjohn Company, Kalamazoo, MI). Sponges containing vehicle alone (PBS) were used as negative controls, while sponges containing 1.0 µg/embryo of human recombinant VEGF 165 (R&D Systems, Abingdon, UK) were used as positive controls. In other experiments, either a VEGF or FGF2 (Santa Cruz) neutralizing antibody was added to sponges containing NGF.
CAMs were examined daily until day 12 and photographed in ovo with a stereomicroscope SR equipped with the Zeiss Camera System MC63. In some experiments, blood vessels entering the sponge within the focal plane of the CAM were counted by two observers in a double-blind fashion at ×50 magnification (23) . At day 12, CAMs were processed for light microscopy. Briefly, the embryos and their membranes were fixed in ovo in Bouin's fluid, dehydrated in graded ethanols, embedded in paraffin, serially sectioned at 7 µm according to a plane perpendicular to their free surface, and stained with a 0.5% aqueous solution of toluidine blue and observed under a light microscope.
Quantitation of the angiogenic response
The angiogenic response was evaluated as microvessel density in the CAM area under the implant. The area occupied by microvessels was estimated by using a morphometric method of "point counting" (24) . Briefly, every third section with 60 serial slides from an individual specimen was analyzed simultaneously by two investigators by a 144-intersection point-square reticulum of 0.125 mm 2 inserted in the eyepiece of a double-headed photomicroscope. Six randomly chosen microscopic fields of each section were evaluated at ×250 magnification for the total number of the intersection points that were occupied by vessels transversally cut (diameter ranging from 3 to 10 µm). Mean values ± SD for vessel counts were determined for each analysis. The vascular density was indicated by the number of the occupied intersection points, expressed as a percentage of the total number of intersection points.
Statistical analysis of results
Results were analyzed by one-or, where appropriate, two-way ANOVA, followed by Fisher's least-significant difference test. A P value <0.05 was considered significant. Significance of differences between the mean values of the intersection points in the experimental CAMs and control CAMs was determined by Student's t-test for unpaired data.
RESULTS
HUVECs express trkA NGFR and p75 NTR mRNAs and proteins
Subconfluent cultures of HUVECs were assessed for their ability to express the NGF receptors trkA NGFR and p75 NTR by RT-PCR analysis. PC12 rat pheochromocytoma cells that express both NGF receptors (25) were used as positive controls. As shown in Figure 1A , both trkA NGFR and p75 NTR transcripts were detected in HUVECs.
Accordingly, immunoprecipitation of the cell extracts followed by Western blotting showed that trkA NGFR and p75 NTR proteins are present in HUVECs (Fig. 1B) , a result confirmed by immunocytochemistry experiments performed on the same batch of HUVEC cultures (data not shown).
NGF/trkA NGFR interaction triggers a mitogenic response in HUVECs
To elucidate the biological significance of NGF receptor expression in endothelial cells, we evaluated the capacity of NGF to exert a mitogenic response in HUVECs. From preliminary experiments, 96 h of stimulation was established as the optimal time to assess the mitogenic potential of the growth factor. As shown in Figure 2 (lower panel), NGF promoted HUVEC proliferation in a concentration-dependent manner. A similar mitogenic effect was observed in HUVEC cultures treated with NGF in the absence of the sustaining factor ECGS (Fig. 2 , upper histogram).
Previous observations had shown that NGF/trkA NGFR interaction exerts a mitogenic response in different cell types (10) (11) (12) . NGF induced a rapid increase of trkA NGFR phosphorylation in HUVECs within 10 min after the addition of the growth factor to the culture medium without significant modification of trkA NGFR protein levels (Fig. 3A) . Preincubation of HUVECs with the specific trkA NGFR inhibitor K252a prevented NGF-induced receptor phosphorylation. Furthermore, K252a completely suppressed the basal level of trkA NGFR phosphorylation observed in NGF-untreated cultures (Fig. 3A) .
Downstream signaling triggered by tyrosine kinase receptor occupancy encompasses the activation of mitogen-activated protein kinase with consequent phosphorylation of ERKs. Accordingly, NGF-induced trkA NGFR phosphorylation was associated to a significant increase of ERK 1/2 phosphorylation (Fig. 3B) . The trkA NGFR inhibitor K252a completely prevented NGFinduced ERK 1/2 activation (Fig. 3B) . As observed for trkA NGFR phosphorylation, K252a suppressed also the basal levels of ERK 1/2 phosphorylation in NGF-untreated cultures.
Preincubation of HUVEC cultures with the MAPKK inhibitor PD98059 (26) resulted in a complete inhibition of NGF-induced ERK 1/2 phosphorylation, which was associated with parallel suppression of the mitogenic response to the growth factor (Fig. 4) . Taken together, the data indicate that NGF/ trkA NGFR trigger a mitogenic response in HUVECs that is mediated by ERK 1/2 activation.
NGF exerts an autocrine role in HUVECs
The capacity of the K252a inhibitor to suppress the basal levels of trkA NGFR and ERK 1/2 phosphorylation in untreated HUVEC culture raises the hypothesis that NGF of endothelial origin may play and autocrine role in HUVECs. To assess this possibility, NGF expression was investigated by RT-PCR analysis and immunocytochemistry in these cells. As expected (Fig. 5) , HUVECs expressed significant levels of NGF mRNA and protein under standard culture conditions. Furthermore, NGF protein expression was dramatically enhanced when cells were maintained under serum-free conditions, as NGF-specific immunostaining increased in a timedependent manner after 24 and 48 h starvation (Fig. 5B) . Note that no viable cells were observed after 60 h of serum-deprivation (data not shown), which suggests that NGF up-regulation may be part of the cell response to nutrient depletion. Further experiments are required to clarify this point.
To assess whether endogenous NGF may exert an autocrine role in HUVEC cultures, we incubated cells in the presence of a NGF-neutralizing antibody or the selective trkA NGFR inhibitor K252a. As shown in Fig. 5C , both substances caused a significant decrease of HUVEC proliferation under standard culture conditions. In addition, a VEGF-neutralizing antibody that could reduce basal HUVEC proliferation by about 10% did not influence NGF-induced HUVEC proliferation.
NGF is angiogenic in the chick embryo CAM
The capacity of NGF to interact directly with endothelial cells in vitro prompted us to evaluate the angiogenic potential of NGF when delivered in vivo to 8-day chick embryo CAM via a gelatin sponge implant (27) .
At day 4 of incubation, macroscopic observation of the CAMs showed that NGF induced an angiogenic response characterized by allantoic vessels that spread radially towards the sponge in a spoked-wheel pattern (Fig. 6A) . No vascular reaction was detectable around the sponges containing PBS (Fig. 6B) .
Microscopically, the sponges adsorbed with NGF showed a collagenous matrix with numerous small blood vessels and fibroblasts localized among the sponge trabeculae (Fig. 6C) . Numerous host capillaries piercing the sponge in some points were also detectable at the boundary between the sponge and the CAM mesenchyme. Similar findings had been reported previously by using VEGF 165 -treated sponges (16) . No collagenous matrix, blood vessels, or fibroblasts were present among the sponge trabeculae in the samples treated with PBS (Fig. 6D) . Accordingly, morphometric evaluation of the vascular density of the CAM at day 12 of incubation demonstrated that NGF exerted an angiogenic effect quantitatively similar to that elicited by VEGF 165 (Table 1 ).
The angiogenic activity of NGF was fully suppressed by neutralizing anti-NGF antibodies, marginally affected by a VEGF neutralizing antiserum and completely unaffected by a FGF2 neutralizing antibody (data not shown).
DISCUSSION
Our results demonstrate that NGF interacts with specific high-affinity trkA NGFR receptors in endothelial cells and elicits a mitogenic response in vitro that is paralleled by the capability of NGF of inducing neovascularization in the CAM of the chick embryo. Several experimental evidences point to the capacity of NGF to exert a direct effect on endothelium.
Expression of both high-affinity trkA NGFR and low-affinity p75 NTR in HUVEC was demonstrated by RT-PCR analysis and Western blotting. NGF caused a rapid phosphorylation of trkA NGFR that was prevented by its staurosporine-related selective inhibitor K252a (13) . In keeping with the role of trkA NGFR in mediating the mitogenic activity of NGF in other cell types (28), K252a abolished the mitogenic activity exerted by NGF in HUVECs. Endothelial cell proliferation triggered by NGF was suppressed also by the MAPKK inhibitor PD98059, thus implicating the ras/raf/MAPK signaling pathway in the biological response of endothelium to NGF. Indeed, NGF caused a rapid phosphorylation of ERK 1/2 , which was prevented by the trkA NGFR inhibitor K252a and by PD98059. Taken together, our results clearly indicate that HUVEC proliferation triggered by NGF is mediated by trkA NGFR via activation of the MAPK pathway, a signal transduction mechanism usually activated by NGF in target cells (29) .
Our data extend previous observations on the ability of NGF to induce cell proliferation and upregulation of cell adhesion molecules in human dermal microvascular endothelial cells (15) , thus suggesting that the responsiveness to NGF represents a widespread property of endothelial cells of different origin. Accordingly, we have shown that NGF induces a potent angiogenic response when delivered to the CAM of the developing chick embryo. In addition, the same assay revealed that NGF also acts as a pleiotropic factor in stimulating collagen deposition and fibroblast proliferation, two effects normally observed for FGF2 (24) .
Recently, Calzà et al. (14) demonstrated that NGF promotes angiogenesis in superior cervical ganglia of the newborn rat. This finding was paralleled by the up-regulation of VEGF and nitric oxide synthase expression, which raises the hypothesis that NGF may exert an indirect proangiogenic effect in vivo. Relevant to this point, we have shown that NGF-induced neovascularization in the chick embryo CAM was fully suppressed by anti-NGF antibodies but was affected only partially by anti-VEGF antibodies and was totally unaffected by anti-FGF2 antibodies. These data, together with the described direct mitogenic effect of NGF on endothelial cells in vitro, suggest that NGF may elicit an angiogenic response in vivo by both direct and indirect mechanism of action. It appears then that VEGF, but not FGF2, is probably a secondary mediator of NGF-induced angiogenesis, in addition to the direct effect of NGF itself. Therefore, NGF released by different cell types (30) may exert a paracrine function on endothelium and stimulate neovascularization. This finding may be remarkably significant in various pathological conditions, including inflammation and tumor growth, processes in which a pivotal role is played by new blood vessel formation. In fact, NGF effects may be of particular relevance to some neoplasms of neural and non-neural origin, including neuroblastoma (5), pheochromocytoma (31) , and breast cancer (28, 32) , in which it may stimulate at the same time the proliferation of tumor parenchymal cells and stromal cells, including endothelium.
Besides its possible paracrine mechanism of action, NGF, our data demonstrate, may play an autocrine role in endothelium. Indeed, we have shown, both at the mRNA (by RT-PCR analysis) and protein (by immunocitochemistry) levels, that HUVECs express NGF. It is thus plausible that this causes partial activation of both the high-affinity trkA NGFR and the related signal transduction molecules ERK 1/2 , leading to phosphorylation under basal conditions. In support to this hypothesis, neutralizing anti-NGF antibodies and the trkA NGFR inhibitor K252a suppressed the basal levels of trkA NGFR and of ERK 1/2 phosphorylation, whereas PD98059 prevented basal phosphorylation of ERK 1/2 .
NGF expression is increased in serum-deprived HUVECs, which suggests that NGF upregulation may be part of endothelial cell response to nutrient/trophic depletion. It is therefore possible to hypothesize that nutrient/trophic shortage, together with hypoxic conditions and the citokine milieu (33), may activate epigenetic autocrine (e.g., NGF production by endothelium) and paracrine (e.g., VEGF production by tumor and stromal cells) signals leading to endothelial cell proliferation/survival, thus contributing to tumor angiogenesis.
In conclusion, we have shown that NGF from exogenous, as well as from endogenous, origin can exert a direct effect on endothelium by activating its high-affinity receptor trkA NGFR . This is paralleled by the capacity of NGF to induce a potent angiogenic response in vivo. Our results may shed a new light on the role of NGF in the developing CNS, inflammation, and tumor growth. Also, they might be exploited in novel protocols of antiangiogenic therapy in NGFproducing tumors. 
